3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
338
Neoplasms, Plasma Cell
62
Recurrence
39
Lymphoma, Non-Hodgkin
37
Leukemia, Lymphocytic, Chronic, B-Cell
35
Lymphoma
31
Hodgkin Disease
31
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Lymphoma, Mantle-Cell
27
Lymphoma, Large B-Cell, Diffuse
27
Immunoglobulin Light-chain Amyloidosis
27
Lymphoma, Follicular
26
Lymphoma, Large-Cell, Immunoblastic
25
Lymphoma, B-Cell, Marginal Zone
25
Leukemia, Myeloid, Acute
25
Neoplasms
24
Burkitt Lymphoma
23
Leukemia, Myeloid, Chronic-Phase
22
Myeloproliferative Disorders
21
Leukemia, Myeloid, Accelerated Phase
21
Leukemia
21
Blast Crisis
21
Primary Myelofibrosis
20
Lymphoma, T-Cell, Cutaneous
20
Leukemia, Hairy Cell
19
Waldenstrom Macroglobulinemia
16
Myelodysplastic Syndromes
16
Leukemia, Myelomonocytic, Chronic
16
Sezary Syndrome
15
Mycosis Fungoides
15
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Amyloid Neuropathies, Familial
×
Plasma cell
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled